• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的病毒脱落:对现有文献的综述。

Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature.

机构信息

Department of Medicine, University of Minnesota Infectious Diseases and International Medicine, Minneapolis, MN, USA.

Division of Infectious Diseases, Department of Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon.

出版信息

Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668. doi: 10.1017/ice.2020.1273. Epub 2020 Oct 20.

DOI:10.1017/ice.2020.1273
PMID:33077007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7691645/
Abstract

OBJECTIVE

Transmission of SARS-CoV-2 has significant implications for hospital infection prevention and control, discharge management, and public health. We reviewed available literature to reach an evidenced-based consensus on the expected duration of viral shedding.

DESIGN

We queried 4 scholarly repositories and search engines for studies reporting SARS-CoV-2 viral shedding dynamics by PCR and/or culture available through September 8, 2020. We calculated the pooled median duration of viral RNA shedding from respiratory and fecal sources.

RESULTS

The review included 77 studies on SARS-CoV-2. All studies reported PCR-based testing and 12 also included viral culture data. Among 28 studies, the overall pooled median duration of RNA shedding from respiratory sources was 18.4 days (95% CI, 15.5-21.3; I2 = 98.87%; P < .01). When stratified by disease severity, the pooled median duration of viral RNA shedding from respiratory sources was 19.8 days (95% CI, 16.2-23.5; I2 = 96.42%; P < .01) among severely ill patients and 17.2 days (95% CI, 14.0-20.5; I2 = 95.64%; P < .01) in mild-to-moderate illness. Viral RNA was detected up to 92 days after symptom onset. Viable virus was isolated by culture from -6 to 20 days relative to symptom onset.

CONCLUSIONS

SARS-COV-2 RNA shedding can be prolonged, yet high heterogeneity exists. Detection of viral RNA may not correlate with infectivity since available viral culture data suggests shorter durations of shedding of viable virus. Additional data are needed to determine the duration of shedding of viable virus and the implications for risk of transmission.

摘要

目的

SARS-CoV-2 的传播对医院感染防控、出院管理和公共卫生具有重要意义。我们查阅了现有文献,就病毒脱落的预期持续时间达成了基于证据的共识。

设计

我们在 2020 年 9 月 8 日之前,通过 4 个学术知识库和搜索引擎查询了报道 SARS-CoV-2 病毒脱落动力学的研究,这些研究通过 PCR 和/或培养进行。我们计算了从呼吸道和粪便来源中病毒 RNA 脱落的汇总中位数持续时间。

结果

该综述包括 77 项关于 SARS-CoV-2 的研究。所有研究均报告了基于 PCR 的检测,其中 12 项研究还包括病毒培养数据。在 28 项研究中,呼吸道来源的 RNA 脱落的总体汇总中位数持续时间为 18.4 天(95%CI,15.5-21.3;I²=98.87%;P<.01)。按疾病严重程度分层,严重患者呼吸道来源的病毒 RNA 脱落的汇总中位数持续时间为 19.8 天(95%CI,16.2-23.5;I²=96.42%;P<.01),轻度至中度疾病患者为 17.2 天(95%CI,14.0-20.5;I²=95.64%;P<.01)。在症状出现后,可检测到病毒 RNA 长达 92 天。通过培养从症状出现前 6 天到 20 天可分离到有活力的病毒。

结论

SARS-CoV-2 RNA 脱落可能延长,但存在高度异质性。由于目前的病毒培养数据表明有活力的病毒脱落持续时间较短,因此检测到病毒 RNA 可能与传染性无关。需要更多的数据来确定有活力的病毒脱落的持续时间及其对传播风险的影响。

相似文献

1
Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature.了解严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的病毒脱落:对现有文献的综述。
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668. doi: 10.1017/ice.2020.1273. Epub 2020 Oct 20.
2
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.SARS-CoV-2、SARS-CoV 和 MERS-CoV 的病毒载量动态、病毒脱落持续时间和传染性:系统评价和荟萃分析。
Lancet Microbe. 2021 Jan;2(1):e13-e22. doi: 10.1016/S2666-5247(20)30172-5. Epub 2020 Nov 19.
3
Differences of Severe Acute Respiratory Syndrome Coronavirus 2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens Among Adult Inpatients With Coronavirus Disease 2019.新型冠状病毒肺炎成年住院患者痰液与鼻咽拭子标本中 2019 年冠状病毒脱落持续时间的差异。
Chest. 2020 Nov;158(5):1876-1884. doi: 10.1016/j.chest.2020.06.015. Epub 2020 Jun 20.
4
Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19.持续的 SARS-CoV-2 RNA 脱落而无传染性证据:一项 COVID-19 患者的队列研究。
J Infect Dis. 2021 Oct 28;224(8):1362-1371. doi: 10.1093/infdis/jiab107.
5
Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.SARS-CoV-2 G614 感染(武汉株)患者新冠病毒载量随症状出现和严重程度的变化轨迹。
JAMA Netw Open. 2022 Jan 4;5(1):e2142796. doi: 10.1001/jamanetworkopen.2021.42796.
6
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19).2019冠状病毒病(COVID-19)患者病毒RNA长期脱落的相关因素
Clin Infect Dis. 2020 Jul 28;71(15):799-806. doi: 10.1093/cid/ciaa351.
7
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.与 SARS-CoV-2 感染住院非重症患者病毒持续排出相关因素及洛匹那韦/利托那韦治疗的影响。
Eur Respir J. 2020 Jul 16;56(1). doi: 10.1183/13993003.00799-2020. Print 2020 Jul.
8
Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.2019 年冠状病毒病患者的胃肠道症状和粪便病毒脱落的流行情况:系统评价和荟萃分析。
JAMA Netw Open. 2020 Jun 1;3(6):e2011335. doi: 10.1001/jamanetworkopen.2020.11335.
9
Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.成人严重急性呼吸综合征冠状病毒 2 感染患者呼吸道和粪便病毒持续排出的危险因素。
J Clin Lab Anal. 2021 Sep;35(9):e23923. doi: 10.1002/jcla.23923. Epub 2021 Aug 13.
10
Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19.SARS-CoV-2 RNA 脱落持续时间及 COVID-19 患者病毒脱落时间延长的相关因素。
J Med Virol. 2021 Jan;93(1):506-512. doi: 10.1002/jmv.26280. Epub 2020 Jul 15.

引用本文的文献

1
Critical illness in immunocompromised patients: insights into relapse or persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): case series report.免疫功能低下患者的危重症:对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)复发或持续感染的见解:病例系列报告
J Med Case Rep. 2025 Jul 27;19(1):371. doi: 10.1186/s13256-025-05431-8.
2
Retrospective Analysis of Factors Associated with a Prolonged Nucleic Acid Conversion Time in Patients with COVID-19 at Fangcang Shelter Hospital.方舱医院新冠肺炎患者核酸转阴时间延长相关因素的回顾性分析
Infect Drug Resist. 2025 Jun 30;18:3219-3229. doi: 10.2147/IDR.S521808. eCollection 2025.
3
Virological Aspects of COVID-19 in Patients with Hematological Malignancies: Duration of Viral Shedding and Genetic Analysis.血液系统恶性肿瘤患者中 COVID-19 的病毒学特征:病毒脱落持续时间及基因分析
Viruses. 2024 Dec 31;17(1):46. doi: 10.3390/v17010046.
4
Personal characteristics and transmission dynamics associated with SARS-CoV-2 semi-quantitative PCR test results: an observational study from Belgium, 2021-2022.个人特征与 SARS-CoV-2 半定量 PCR 检测结果相关因素:2021-2022 年比利时的一项观察性研究。
Front Public Health. 2024 Sep 10;12:1429021. doi: 10.3389/fpubh.2024.1429021. eCollection 2024.
5
Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19.洛匹那韦/利托那韦与瑞德西韦在降低COVID-19患者病毒载量及病毒脱落持续时间方面的疗效相当。
Microorganisms. 2024 Aug 16;12(8):1696. doi: 10.3390/microorganisms12081696.
6
Symptom propagation in respiratory pathogens of public health concern: a review of the evidence.公共卫生关注的呼吸道病原体的症状传播:证据综述。
J R Soc Interface. 2024 Jul;21(216):20240009. doi: 10.1098/rsif.2024.0009. Epub 2024 Jul 24.
7
COVID-19 cluster surveillance using exposure data collected from routine contact tracing: The genomic validation of a novel informatics-based approach to outbreak detection in England.利用常规接触者追踪收集的暴露数据进行新冠病毒病聚集性监测:英国一种基于信息学的新型疫情检测方法的基因组验证
PLOS Digit Health. 2024 Apr 25;3(4):e0000485. doi: 10.1371/journal.pdig.0000485. eCollection 2024 Apr.
8
Optimal initial insulin dosage for managing steroid-induced hyperglycemia in hospitalized COVID-19 patients: A retrospective single-center study.住院COVID-19患者中管理类固醇诱导的高血糖的最佳初始胰岛素剂量:一项回顾性单中心研究。
SAGE Open Med. 2024 Mar 20;12:20503121241238148. doi: 10.1177/20503121241238148. eCollection 2024.
9
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset.SARS-CoV-2 病毒复制在症状出现后数周内在人体肺部持续存在。
Am J Respir Crit Care Med. 2024 Apr 1;209(7):840-851. doi: 10.1164/rccm.202308-1438OC.
10
Difficulty in management of acute invasive fungal rhinosinusitis in Indonesia during the COVID-19 pandemic: A case report.印度尼西亚在新冠疫情期间急性侵袭性真菌性鼻-鼻窦炎的管理难点:一例病例报告
Respir Med Case Rep. 2023 Sep 16;46:101916. doi: 10.1016/j.rmcr.2023.101916. eCollection 2023.

本文引用的文献

1
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).COVID-19 住院患者中感染性病毒排出的持续时间和关键决定因素。
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
2
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.在新冠肺炎患者血液制品中检测到的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)RNA与传染性病毒无关。
Wellcome Open Res. 2020 Oct 12;5:181. doi: 10.12688/wellcomeopenres.16002.2. eCollection 2020.
3
Duration of SARS-CoV-2 detection in Israel Defense Forces soldiers with mild COVID-19.以色列国防军轻症新冠病毒肺炎士兵中新冠病毒2检测的持续时间。
J Med Virol. 2021 Feb;93(2):608-610. doi: 10.1002/jmv.26374. Epub 2020 Aug 13.
4
High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease.SARS-CoV-2 RNAemia 高频发生,与重症疾病相关。
Clin Infect Dis. 2021 May 4;72(9):e291-e295. doi: 10.1093/cid/ciaa1054.
5
Persistent SARS-COV-2 RNA positivity in a patient for 92 days after disease onset: A case report.一名患者在疾病发作后92天内SARS-CoV-2 RNA持续呈阳性:病例报告。
Medicine (Baltimore). 2020 Aug 21;99(34):e21865. doi: 10.1097/MD.0000000000021865.
6
Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.SARS-CoV-2 鼻咽拭子 PCR 阳性在 COVID-19 恢复期血浆供者中的持续存在。
Transfusion. 2020 Dec;60(12):2962-2968. doi: 10.1111/trf.16015. Epub 2020 Aug 24.
7
Repeated COVID-19 relapse during post-discharge surveillance with viral shedding lasting for 67 days in a recovered patient infected with SARS-CoV-2.在对感染 SARS-CoV-2 的康复患者进行出院后监测期间,出现了反复的 COVID-19 复发,病毒脱落持续了 67 天。
J Microbiol Immunol Infect. 2021 Feb;54(1):101-104. doi: 10.1016/j.jmii.2020.07.017. Epub 2020 Aug 6.
8
Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea.韩国社区治疗中心中无症状和有症状的 SARS-CoV-2 感染患者的临床病程和分子病毒脱落情况。
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452. doi: 10.1001/jamainternmed.2020.3862.
9
Comparative study on virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients.新型冠状病毒肺炎患者鼻咽和粪便标本病毒脱落模式的比较研究
Sci China Life Sci. 2021 Mar;64(3):486-488. doi: 10.1007/s11427-020-1783-9. Epub 2020 Aug 5.
10
Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19.新型冠状病毒肺炎患者病毒 RNA 脱落停止的临床预测指标和时间。
J Clin Virol. 2020 Sep;130:104577. doi: 10.1016/j.jcv.2020.104577. Epub 2020 Aug 5.